FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)

Featured In: Regulatory News

By Federal Drug Administration Friday, January 29, 2024

Loading...

FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)

 

Safety Announcement

Additional Information for Patients

Additional Information for Healthcare Professionals

Data Summary

 

Safety Announcement 

[01-29-2010] The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals and patients about a rare, but serious, complication in the liver known as non-cirrhotic portal hypertension in patients using Videx or Videx EC (didanosine). Didanosine is a medication used to treat human immunodeficiency virus (HIV) infection. Videx was the first approved didanosine medication. Videx EC is a delayed-release version of Videx. 

Non-cirrhotic portal hypertension (portal hypertension that is not caused by cirrhosis of the liver) is rare in the United States. It occurs when blood flow in the major vein in the liver (the portal vein) slows down. This slowed blood flow can lead to the development of severely enlarged esophageal veins (varices) in the gastrointestinal system. Because esophageal varices are thin and portal hypertension increases the pressure of blood flow in these veins, esophageal varices can break open. This can result in serious bleeding and, in some cases, death.

FDA became aware of cases of non-cirrhotic portal hypertension through adverse event reports submitted to FDA's Adverse Event Reporting System (AERS). Based on these reports, FDA has revised the didanosine drug label to include information about non-cirrhotic portal hypertension to help ensure the safe use of this drug.

FDA believes the clinical benefits of didanosine for certain patients with HIV continue to outweigh its potential risks. The decision to use this drug, however, must be made on an individual basis between the treating physician and the patient.

 

Additional Information for Patients

  • Didanosine is a prescription medication used along with other drugs to treat patients who are infected with HIV, the virus that causes AIDS.
  • Didanosine works by reducing the growth of HIV.It belongs to a class of medications called nucleoside analogues.
  • Didanosine helps your body maintain its supply of immune cells called CD4 cells. These cells are important for fighting HIV and other infections.
  • Non-cirrhotic portal hypertension is a serious, but rare, side effect that has occurred in patients using didanosine.

 

Additional Information for Healthcare Professionals

  • Be aware that didanosine use has been associated with the development of non-cirrhotic portal hypertension.
  • Discuss with patients the clinical benefits and potential risks, including the risk of non-cirrhotic portal hypertension, with the use of didanosine.
  • Continue to monitor patients for the development of portal hypertension and esophageal varices.
  • Be aware that didanosine already has a Boxed Warning for lactic acidosis and hepatomegaly with steatosis.
  • Didanosine in combination with other antiretroviral agents as well as hydroxyurea or ribavirin has been associated with the development of liver toxicity.

 

Data Summary

FDA's decision to revise the drug label for didanosine is based on post-marketing reports of patients developing non-cirrhotic portal hypertension while using didanosine. Other liver adverse events such as lactic acidosis, hepatomegaly with steatosis, and liver failure have been reported with the use of didanosine alone and in combination with other antiviral drugs.

Of the 42 post-marketing cases of non-cirrhotic portal hypertension in patients using didanosine:

  • Twenty-six were males, 14 were females, and in two no gender was specified.
  • The ages ranged from 10 years to 66 years.
  • Duration of didanosine treatment ranged from months to years before development of non-cirrhotic portal hypertension.
  • Definitive cases of non-cirrhotic portal hypertension were confirmed by biopsy and had no alternative etiology for the diagnosis.

Medical interventions described in the reported cases included:

  • Banding/ligation of esophageal varices in 8 patients.
  • Transjugular intrahepatic portosystemic shunt (TIPSS) procedure in three patients.
  • Liver transplantation in 3 patients.

There were four deaths total in the 42 reported cases. The cause of death in the four patients was due to:

  • Hemorrhage from esophageal varices in two patients.
  • Progressive liver failure in one patient.
  • A combination of multi-organ failure, cerebral hemorrhage, sepsis, and lactic acidosis in one patient.

The only patients who have been reported as fully recovered are the three non-cirrhotic portal hypertension patients who received a liver transplant.

A causal association is difficult to determine from postmarketing reports alone. However, based on the number of well-documented cases and exclusion of other causes of portal hypertension such as alcohol-related cirrhosis or hepatitis C, FDA concludes there is an association between use of didanosine and development of non-cirrhotic portal hypertension. Because of the potential severity of portal hypertension, including death from hemorrhaging esophageal varices, FDA has revised the Warning and Precautions section of the didanosine drug label to assure safe use of the medication.

 

    

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Publishing Data That Conform to the MIQE Guidelines

Jan 22

Minimum information for publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines help researchers design qPCR experiments.

Calibration Free Analysis to Measure the Concentration of Active Proteins

Nov 23 2009

An SPR-based method, Calibration Free Concentration Analysis can be used to accurately determine the concentration of active protein in a sample, relating to the specific binding activity of the protein, and without the need for a standard.

Advances in EMCCD Technology: Making Imaging Less Arbitrary

Nov 16 2009

Recent advances in EMCCD technology have solved the problem of non-standardized measurement units by using the photoelectron to standardize imaging experiments.

10 Tips for Successful Sample Concentration and Buffer Exchange

Nov 6 2009

Centrifugal devices with ultrafiltration (UF) membrane can solve common problems researchers face when working with proteins.

Advantages of Monolithic Laser Combiner Technology in Confocal Microscopy Systems

Jan 6

Fluorescence microscopy techniques require a reliable light source at the desired wavelength or wavelengths, with minimal downtime for maintenance and alignment. Lasers are a popular light source, although the alignment and upkeep of laser combiners is a time-consuming prospect for many users.

Size-Exclusion Chromatography for Purification of Biomolecules

Dec 2 2009

Size-exclusion chromatography (SEC) is a popular method to separate biomolecules based on their size. Primarily, it is applied to the separation of biopolymers such as proteins and nucleic acids, i.e. water-soluble polymers.

Improving Separation During Electrophoresis

Dec 2 2009

SeparateIT gels represent a novel gel matrix for DNA electrophoresis. Gel polymers are arranged in a conceptually different way, in accordance with a new theoretical model of gel electrophoresis.

Improving Quality of ELISA

Dec 2 2009

Using ready-to-use ELISA kits from manufacturers is easy and convenient. Sometimes however, home-made ELISA is required because there is no kit available with the right antibodies or the characteristics of the available kits such as their limits of detection are not appropriate.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Mechanisms of plasticity in simple taxis behaviors in Drosophila

Nov 8 2009

Like the proverbial moth drawn to the candle flame, the fruit fly Drosophila also stereotypically approaches light sources. This positive phototaxis is the archetypal example of hard-wired input-output behaviors.

Does amplitude-modulated frequency have a role in the hypoalgesic response of interferential current on pressure pain sensitivity in healthy subjects? A randomised crossover s...

19 hours ago

OBJECTIVE: To investigate the hypoalgesic effect of amplitude-modulated frequency during interferential current therapy using an experimentally induced mechanical pain model in normal subjects. This study examined pain pressure sensitivities achieved when the...

Preview: ChemBioChem 4/2010

22 hours ago

No Abstract

Frontiers of Chemistry in Paris

22 hours ago

No Abstract

A comparison of the perceptions and aspirations of third-year physiotherapy students trained in three educational settings in Poland.

Feb 5

OBJECTIVES: In Poland, physiotherapy is offered at three types of school: medical universities, universities of physical education, and schools that do not specialise in either the medical sciences or physical education. This study explored the knowledge of students who were...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Neuroscience Diseases of The Brain and How The Mind Emerges

Neuroscience Diseases of The Brain and How The Mind Emerges

Nov 8 2009

Dennis Choi, director of Emory Universitys Neuroscience Center, is renowned for his groundbreaking research on brain and spinal cord injury.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: